A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
Authors
Keywords
-
Journal
NATURE MEDICINE
Volume 25, Issue 12, Pages 1938-1947
Publisher
Springer Science and Business Media LLC
Online
2019-12-03
DOI
10.1038/s41591-019-0668-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
- (2019) Rumani Singh et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase
- (2019) Blake E. Smith et al. Nature Communications
- Retromer facilitates the localization of Bcl-xL to the mitochondrial outer membrane
- (2019) Trey Farmer et al. MOLECULAR BIOLOGY OF THE CELL
- BCL-2 as therapeutic target for hematological malignancies
- (2018) Guilherme Fleury Perini et al. Journal of Hematology & Oncology
- Plasticity in binding confers selectivity in ligand-induced protein degradation
- (2018) Radosław P. Nowak et al. Nature Chemical Biology
- Interferon regulatory factor 8 regulates caspase-1 expression to facilitate Epstein-Barr virus reactivation in response to B cell receptor stimulation and chemical induction
- (2018) Dong-Wen Lv et al. PLoS Pathogens
- Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action
- (2018) Kristin M. Riching et al. ACS Chemical Biology
- Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas
- (2018) Raphael Koch et al. BLOOD
- Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?
- (2017) Ian Churcher JOURNAL OF MEDICINAL CHEMISTRY
- Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells
- (2017) D T Saenz et al. LEUKEMIA
- Structural basis of PROTAC cooperative recognition for selective protein degradation
- (2017) Morgan S Gadd et al. Nature Chemical Biology
- From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
- (2017) Avi Ashkenazi et al. NATURE REVIEWS DRUG DISCOVERY
- Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy
- (2016) Nobumichi Ohoka et al. CURRENT CANCER DRUG TARGETS
- Chemical genetics approaches for selective intervention in epigenetics
- (2016) Andrew C Runcie et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Venetoclax: First Global Approval
- (2016) Emma D. Deeks DRUGS
- Patient-derived xenografts: a relevant preclinical model for drug development
- (2016) Luca Pompili et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
- (2016) András Kotschy et al. NATURE
- The Perseus computational platform for comprehensive analysis of (prote)omics data
- (2016) Stefka Tyanova et al. NATURE METHODS
- Induced protein degradation: an emerging drug discovery paradigm
- (2016) Ashton C. Lai et al. NATURE REVIEWS DRUG DISCOVERY
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
- (2016) Kanak Raina et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Computationally designed high specificity inhibitors delineate the roles of BCL2 family proteins in cancer
- (2016) Stephanie Berger et al. eLife
- Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
- (2015) Michael Zengerle et al. ACS Chemical Biology
- Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL
- (2015) Ashton C. Lai et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- The BCL-2 protein family, BH3-mimetics and cancer therapy
- (2015) A R D Delbridge et al. CELL DEATH AND DIFFERENTIATION
- Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
- (2015) Jing Lu et al. CHEMISTRY & BIOLOGY
- Attacking cancer's Achilles heel: antagonism of anti-apoptotic BCL-2 family members
- (2015) Joseph T. Opferman FEBS Journal
- Prime time for PROTACs
- (2015) Raymond J Deshaies Nature Chemical Biology
- Catalytic in vivo protein knockdown by small-molecule PROTACs
- (2015) Daniel P Bondeson et al. Nature Chemical Biology
- Phthalimide conjugation as a strategy for in vivo target protein degradation
- (2015) G. E. Winter et al. SCIENCE
- Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
- (2015) Joel D. Leverson et al. Science Translational Medicine
- Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia
- (2014) Aksana Kaefer et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity
- (2014) Zhi-Fu Tao et al. ACS Medicinal Chemistry Letters
- Only severe thrombocytopenia results in bleeding and defective thrombus formation in mice
- (2013) M. Morowski et al. BLOOD
- The complex transcriptional landscape of the anucleate human platelet
- (2013) Paul F Bray et al. BMC GENOMICS
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Next Generation Sequencing Analysis of Human Platelet PolyA+ mRNAs and rRNA-Depleted Total RNA
- (2013) Antheia Kissopoulou et al. PLoS One
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Targeting the Bcl-2 family for cancer therapy
- (2012) Shibu Thomas et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- The Proteomics Identifications (PRIDE) database and associated tools: status in 2013
- (2012) Juan Antonio Vizcaíno et al. NUCLEIC ACIDS RESEARCH
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- BCL2/BCL-XL inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation
- (2011) M. Vogler et al. BLOOD
- Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets
- (2011) S. M. Schoenwaelder et al. BLOOD
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo
- (2011) J. Chen et al. MOLECULAR CANCER THERAPEUTICS
- The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo
- (2010) Scott Ackler et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Mcl-1 and Bcl-xL cooperatively maintain integrity of hepatocytes in developing and adult murine liver
- (2009) Hayato Hikita et al. HEPATOLOGY
- Universal sample preparation method for proteome analysis
- (2009) Jacek R Wiśniewski et al. NATURE METHODS
- Bcl-2-family proteins and hematologic malignancies: history and future prospects
- (2008) J. C. Reed BLOOD
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now